UBS maintains Amrize at Neutral, raises price target to $46 from $42

UBS kept Amrize rated Neutral and raised its price target to $46 from $42. The new target suggests 12.5% upside versus the Nov 13 close of $40.89. Recent analyst targets for Amrize range from $35.20 to $52.

Original reporting
Published Nov 16, 2026, 4:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Amrize at Neutral, raises price target to $46 from $42 — source image
Decision brief

The 30-second read

$AMRZBullishLow
01

Why it matters

A higher target can attract incremental speculative interest, but without new earnings, guidance, or deal information, it is unlikely to drive a sustained repricing.

02

Market read

Valuation sentiment may improve modestly, but the lack of new fundamentals keeps the trading impact limited.

03

What to watch

Traders may already have priced in recent target dispersion ($35.20 to $52 over 30 days), reducing incremental impact from UBS’s update.

Relevance 4/10Novelty 4/10Timing: today’s analyst note update

Background

The piece summarizes UBS’s latest stance on Amrize, including the updated price target and the recent range of other analysts’ targets.

Company-level read

Ticker impact

$AMRZBullishMedium confidence
Context

UBS maintained Amrize at Neutral and raised its price target to $46 from $42, implying a higher valuation versus the Nov 13 close.

Expected impact

Likely mild upward bias as traders price in the higher target, but limited follow-through risk because the rating stays Neutral.

Evidence & confidence

The article provides only an analyst target change and no new company-specific operational or financial disclosure.

Market effects

Minimal, since this is a single-name target change without sector-wide new information.

None indicated.

None indicated.

Counterpoint

Because the rating remains Neutral, the target hike may reflect model recalibration rather than improved fundamentals, limiting upside follow-through.

Key entities

  • UBS

    Maintained Amrize at Neutral and raised the price target to $46 from $42.

  • Amrize

    Subject of the analyst rating and price-target update.

Related articles

$AMRZHigh

Jefferies downgrades Amrize stock rating on margin concerns

Jefferies downgraded Amrize (NYSE:AMRZ) to Underperform, cutting its price target to $35.20 from $42.80. Analyst Glynis Johnson cited margin concerns due to rising costs and tough comparisons in 2027. The stock is down 23% year-to-date. Jefferies forecasts continued cost pressures will impact margins. Amrize reported Q3 2026 earnings beating profit estimates but missing revenue targets.

$BETAMed

5 Stocks Analysts Just Downgraded

Wall Street analysts downgraded five stocks: BETA Technologies (BETA), TransUnion (TRU), Molson Coors (TAP), Amrize (AMRZ), and another. Downgrades cited delivery delays, slower growth, soft demand, and cost pressures. BETA's Q3 revenue doubled, but deliveries were delayed. TransUnion's revenue rose 12.2%, but margins slipped. Molson Coors saw net sales fall 1.6% and lowered earnings guidance. Amrize adjusted EBITDA and revenue forecasts due to cost inflation.

Med

Amrize Q3 2026 slides: pricing drives margins amid volume headwinds

Amrize reported Q3 2026 revenues of $3.77B, up 2.2% YoY, with net income rising 3.3% to $558M. Pricing initiatives and acquisitions offset volume declines due to weather. Building Materials segment grew 1.8%, while Building Envelope faced challenges. Guidance updated to $12.2B-$12.4B in revenue and $2.95B-$3.05B in adjusted EBITDA for 2026.

$AMRZMed

DA Davidson raises Amrize stock price target to $43 on mixed Q3

DA Davidson raised its price target for Amrize (NYSE:AMRZ) to $43, citing mixed Q3 results with strong Building Materials offset by Building Envelope pressure. The stock is up 5.5% weekly but down 22% in six months. Amrize guided below consensus but beat EPS estimates by 2.06% while missing revenue by 0.95%. DA Davidson maintains a Neutral rating, awaiting more execution visibility.

$AMRZHighAI 9/10

What Amrize (AMRZ) Said on Its Q3 Earnings Call

Amrize (AMRZ) reported Q3 revenue growth of 1.8% to $2.8B in Building Materials and 3.6% to $929M in Building Envelope. Adjusted EBITDA rose 2.7% in Building Materials but fell 14.6% in Building Envelope due to higher costs. The company expects price-over-cost positivity in Building Envelope by 2027. Amrize reaffirmed its 2026 outlook, targeting $12.2B-$12.4B in revenue and $2.95B-$3.05B in EBITDA. It returned $1.1B to shareholders through dividends and repurchases.

$AMRZMed

Amrize Ltd (AMRZ) Q3 2026 Earnings Call Highlights: Pricing Power Drives Growth

Amrize Ltd (AMRZ) reported Q3 2026 earnings, with revenue and EBITDA guidance updated to $12.2-$12.4B and $2.95-$3.05B. Cement volumes fell 4.2% YoY due to weather, while building envelope EBITDA declined 14.6% from inflation. Price-cost positivity in building envelope delayed to 2027. CEO Jan Jenisch expects 2027 growth but cites inflation and interest rate uncertainties. Free cash flow conversion below 50% target due to higher CapEx.